Metabolic syndrome and its association with nonalcoholic steatohepatitis

Bril, Fernando; Sanyal, Arun; Cusi, Kenneth

doi:10.1016/j.cld.2023.01.002

Cited by 52Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and LipoproteinsDiet, Metabolism, and Disease

Metabolic syndrome and its association with nonalcoholic steatohepatitis

Open access

Bril, Fernando, Sanyal, Arun, Cusi, Kenneth·2023·Clinics in Liver Disease

DOI 10.1016/j.cld.2023.01.002

Open this paper in CoChat — free account

Abstract

The relationship between insulin resistance, metabolic syndrome (MetS), and nonalcoholic fatty liver disease (NAFLD) is complicated. Although insulin resistance is almost universal in people with NAFLD and MetS, NAFLD may be present without features of MetS and vice versa. While NAFLD has a strong correlation with cardiometabolic risk factors, these are not intrinsic components of this condition. Taken together, our knowledge gaps call for caution regarding the common assertion that NAFLD is the hepatic manifestation of the MetS, and for defining NAFLD in broad terms as a "metabolic dysfunction" based on a diverse and poorly understood constellation of cardiometabolic features.

Integrity signals

Registry

Crossref · 10.1016/j.cld.2023.01.002

Cites

149 of 149 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Insulin resistance also associates with cardiometabolic risk factors and represents a key feature of the metabolic syndrome, particularly obesity and T2D.
“Thereby, insulin resistance also associates with cardiometabolic risk factors and represents a key feature of the metabolic syndrome, particularly obesity and T2D. 216,217”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [217]

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239 · see citing works
Self-citation
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836 · see citing works
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472 · see citing works
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354 · see citing works
Self-citation
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · see citing works
Self-citation
MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286 · see citing works
Self-citation
Mechanisms of Insulin Action and Insulin Resistance
Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028 · see citing works
Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis
Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492 · see citing works
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203 · see citing works
A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039 · see citing works
Self-citation
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827 · see citing works
Self-citation
The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux
Samuel, V. T., & Shulman, G. I. (2016) · Journal of Clinical Investigation · doi:10.1172/jci77812 · Cited by 1,484 · see citing works
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
Promrat, K., Kleiner, D. E., Niemeier, H. M., Jackvony, E., Kearns, M., Wands, J. R., Fava, J. L., & Wing, R. R. (2010) · Hepatology · doi:10.1002/hep.23276 · Cited by 1,330 · see citing works
Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents
Lavine, J. E. (2011) · JAMA · doi:10.1001/jama.2011.520 · Cited by 1,105 · see citing works
Lipotoxicity in the Pathogenesis of Obesity-Dependent NIDDM: Genetic and Clinical Implications
Unger, R. H. (1995) · Diabetes · doi:10.2337/diab.44.8.863 · Cited by 1,100 · see citing works
Metabolically healthy obesity
Blüher, M. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa004 · Cited by 1,090 · see citing works
Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease
Lambert, J. E., Ramos–Roman, M. A., Browning, J. D., & Parks, E. J. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.11.049 · Cited by 1,069 · see citing works
Metabolic Inflammation and Insulin Resistance in Obesity
Wu, H., & Ballantyne, C. M. (2020) · Circulation Research · doi:10.1161/circresaha.119.315896 · Cited by 1,059 · see citing works
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial
Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1774 · Cited by 1,024 · see citing works
Self-citation
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
Cusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., Kashyap, S., Mechanick, J. I., Mouzaki, M., Nadolsky, K., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.010 · Cited by 1,021 · see citing works
Self-citation
Fuel selection in human skeletal muscle in insulin resistance: a reexamination.
Kelley, D. E., & Mandarino, L. J. (2000) · Diabetes · doi:10.2337/diabetes.49.5.677 · Cited by 1,017 · see citing works
Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis
Ye, Q., Zou, B., Yeo, Y. H., Li, J., Huang, D. Q., Wu, Y., Yang, H., Liu, C., Kam, L. Y., Tan, X. X. E., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30077-7 · Cited by 925 · see citing works
Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications
Cusi, K. J. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.003 · Cited by 917 · see citing works
Self-citation
Reversal of Nonalcoholic Hepatic Steatosis, Hepatic Insulin Resistance, and Hyperglycemia by Moderate Weight Reduction in Patients With Type 2 Diabetes
Petersen, K. F., Dufour, S., Befroy, D., Lehrke, M., Hendler, R. E., & Shulman, G. I. (2005) · Diabetes · doi:10.2337/diabetes.54.3.603 · Cited by 911 · see citing works
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Francque, S. M., Bedossa, P., Ratziu, V., Anstee, Q. M., Bugianesi, E., Sanyal, A. J., Loomba, R., Harrison, S. A., Balabanska, R., Mateva, L., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2036205 · Cited by 801 · see citing works
Self-citation
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795 · see citing works
The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease
Ryan, M. C., Itsiopoulos, C., Thodis, T., Ward, G., Trost, N., Hofferberth, S., O’Dea, K., Desmond, P. V., Johnson, N. A., & Wilson, A. M. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.02.012 · Cited by 778 · see citing works
Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease
Smith, G. I., Shankaran, M., Yoshino, M., Schweitzer, G. G., Chondronikola, M., Beals, J. W., Okunade, A. L., Patterson, B. W., Nyangau, E., Field, T., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134165 · Cited by 771 · see citing works
Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?
Lonardo, A., Nascimbeni, F., Mantovani, A., & Targher, G. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.021 · Cited by 737 · see citing works
Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome
Lonardo, A., Ballestri, S., Marchesini, G., Angulo, P., & Loria, P. (2014) · Digestive and Liver Disease · doi:10.1016/j.dld.2014.09.020 · Cited by 685 · see citing works
Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)
Kuchay, M. S., Krishan, S., Mishra, S. K., Farooqui, K. J., Singh, M. K., Wasir, J. S., Bansal, B., Kaur, P., Jevalikar, G., Gill, H. K., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0165 · Cited by 662 · see citing works
The Origins and Drivers of Insulin Resistance
Johnson, A. M. F., & Olefsky, J. M. (2013) · Cell · doi:10.1016/j.cell.2013.01.041 · Cited by 639 · see citing works
Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss
Johnson, N. A., Sachinwalla, T., Walton, D. W., Smith, K., Armstrong, A., Thompson, M. W., & George, J. (2009) · Hepatology · doi:10.1002/hep.23129 · Cited by 631 · see citing works
Ethnic Differences in the Relationship Between Insulin Sensitivity and Insulin Response
Kodama, K., Tojjar, D., Yamada, S., Toda, K., Patel, C. J., & Butte, A. J. (2013) · Diabetes Care · doi:10.2337/dc12-1235 · Cited by 599 · see citing works
Relationship between obesity, insulin resistance, and coronary heart disease risk
Abbasi, F., Brown, B. W., Lamendola, C. A., McLaughlin, T., & Reaven, G. M. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02051-x · Cited by 574 · see citing works
Metabolic flexibility and insulin resistance
Galgani, J. E., Moro, C., & Ravussin, E. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90558.2008 · Cited by 532 · see citing works
Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss
Hallsworth, K., Fattakhova, G., Hollingsworth, K. G., Thoma, C., Moore, S., Taylor, R., Day, C. P., & Trenell, M. I. (2011) · Gut · doi:10.1136/gut.2011.242073 · Cited by 529 · see citing works
Effect of Calorie Restriction With or Without Exercise on Insulin Sensitivity, β-Cell Function, Fat Cell Size, and Ectopic Lipid in Overweight Subjects
Larson-Meyer, D. E., Heilbronn, L. K., Redman, L. M., Newcomer, B. R., Frisard, M. I., Anton, S., Smith, S. R., Alfonso, A., Ravussin, E., & the Pennington CALERIE Team (2006) · Diabetes Care · doi:10.2337/dc05-2565 · Cited by 504 · see citing works
Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease
de Vries, A. P. J., Ruggenenti, P. L., Ruan, X. Z., Praga, M., Cruzado, J. M., Bajema, I. M., D’Agati, V. D., Lamb, H. J., Barlovič, D. P., Hojs, R., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70065-8 · Cited by 503 · see citing works
Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial†‡§
Harrison, S. A., Fecht, W., Brunt, E. M., & Neuschwander‐Tetri, B. A. (2009) · Hepatology · doi:10.1002/hep.22575 · Cited by 470 · see citing works
Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease
Lomonaco, R., Ortiz‐Lopez, C., Orsak, B., Webb, A., Hardies, J., Darland, C., Finch, J., Gastaldelli, A., Harrison, S. A., Tio, F. O., et al. (2011) · Hepatology · doi:10.1002/hep.25539 · Cited by 461 · see citing works
Self-citation
Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis
Musso, G., Cassader, M., Paschetta, E., & Gambino, R. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.9607 · Cited by 449 · see citing works
Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction
Kirk, E., Reeds, D. N., Finck, B. N., Mayurranjan, M. S., Patterson, B. W., & Klein, S. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.01.048 · Cited by 440 · see citing works
Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies
Jarvis, H., Craig, D., Barker, R., Spiers, G., Stow, D., Anstee, Q. M., & Hanratty, B. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003100 · Cited by 434 · see citing works
Saturated fat is more metabolically harmful for the human liver than unsaturated fat or simple sugars
Luukkonen, P. K., Sädevirta, S., Zhou, Y., Kayser, B., Ali, A., Ahonen, L., Lallukka, S., Pelloux, V., Gaggini, M., Jian, C., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0071 · Cited by 428 · see citing works
From NAFLD to MAFLD: Implications of a Premature Change in Terminology
Younossi, Z. M., Rinella, M. E., Sanyal, A. J., Harrison, S. A., Brunt, E. M., Goodman, Z. D., Cohen, D. E., & Loomba, R. S. (2020) · Hepatology · doi:10.1002/hep.31420 · Cited by 419 · see citing works
Self-citation
Role of free fatty acids in endothelial dysfunction
Ghosh, A., Gao, L., Thakur, A., Siu, P. M., & Lai, C. W. K. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0357-5 · Cited by 418 · see citing works
Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
Eriksson, J. W., Lundkvist, P., Jansson, P.-A., Johansson, L., Kvarnström, M., Moris, L., Miliotis, T., Forsberg, G.-B., Risérus, U., Lind, L., et al. (2018) · Diabetologia · doi:10.1007/s00125-018-4675-2 · Cited by 396 · see citing works
Saroglitazar, a PPAR-α/γ agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial
Gawrieh, S., Noureddin, M., Loo, N., Mohseni, R., Awasty, V., Cusi, K., Kowdley, K. V., Lai, M., Schiff, E., Parmar, D., et al. (2021) · Hepatology · doi:10.1002/hep.31843 · Cited by 379 · see citing works
Self-citation
Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes
Lazo, M., Solga, S. F., Horska, A., Bonekamp, S., Diehl, A. M., Brancati, F. L., Wagenknecht, L. E., Pi-Sunyer, F. X., Kahn, S. E., Clark, J. M., et al. (2010) · Diabetes Care · doi:10.2337/dc10-0856 · Cited by 367 · see citing works
The many actions of insulin in skeletal muscle, the paramount tissue determining glycemia
Sylow, L., Tokarz, V. L., Richter, E. A., & Klip, A. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.03.020 · Cited by 366 · see citing works
Ethnic differences in hepatic steatosis
Guerrero, R., Vega, G. L., Grundy, S. M., & Browning, J. D. (2008) · Hepatology · doi:10.1002/hep.22726 · Cited by 365 · see citing works
Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial
Kahl, S., Gancheva, S., Straßburger, K., Herder, C., Machann, J., Katsuyama, H., Kabisch, S., Henkel, E., Kopf, S., Lagerpusch, M., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0641 · Cited by 360 · see citing works
Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 randomized trial)
Bacchi, E., Negri, C., Targher, G., Faccioli, N., Lanza, M., Zoppini, G., Zanolin, E., Schena, F., Bonora, E., & Moghetti, P. (2013) · Hepatology · doi:10.1002/hep.26393 · Cited by 350 · see citing works
Insulin: The master regulator of glucose metabolism
Norton, L., Shannon, C. E., Gastaldelli, A., & DeFronzo, R. A. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155142 · Cited by 350 · see citing works
Community-based lifestyle modification programme for non-alcoholic fatty liver disease: A randomized controlled trial
Wong, V. W., Chan, R., Wong, G. L., Cheung, B., Chu, C. W., Yeung, D. K., Chim, A. M., Lai, J. W.-Y., Li, L. S., Sea, M. M.-M., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.04.013 · Cited by 346 · see citing works
β Cell dysfunction during progression of metabolic syndrome to type 2 diabetes
Hudish, L. I., Reusch, J. E. B., & Sussel, L. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129188 · Cited by 343 · see citing works
Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action
Bril, F., & Cusi, K. (2017) · Diabetes Care · doi:10.2337/dc16-1787 · Cited by 341 · see citing works
Self-citation
Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk
Muzurović, E. M., Mikhailidis, D. P., & Mantzoros, C. S. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154770 · Cited by 339 · see citing works
Effects of Diet and Exercise on Muscle and Liver Intracellular Lipid Contents and Insulin Sensitivity in Type 2 Diabetic Patients
Tamura, Y., Tanaka, Y., Sato, F., Choi, J. B., Watada, H., Niwa, M., Kinoshita, J., Ooka, A., Kumashiro, N., Igarashi, Y., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1959 · Cited by 334 · see citing works
Short-term weight loss and hepatic triglyceride reduction: evidence of a metabolic advantage with dietary carbohydrate restriction
Browning, J. D., Baker, J. A., Rogers, T., Davis, J., Satapati, S., & Burgess, S. C. (2011) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.110.007674 · Cited by 328 · see citing works
Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies
Sunny, N. E., Bril, F., & Cusi, K. J. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.11.006 · Cited by 321 · see citing works
Self-citation
Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects
Haufe, S., Engeli, S., Kast, P., Böhnke, J., Utz, W., Haas, V., Hermsdorf, M., Mähler, A., Wiesner, S., Birkenfeld, A. L., et al. (2011) · Hepatology · doi:10.1002/hep.24242 · Cited by 307 · see citing works
Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease
Bril, F., Barb, D., Portillo-Sánchez, P., Biernacki, D., Lomonaco, R., Suman, A., Weber, M. H., Budd, J. T., Lupi, M. E., & Cusi, K. J. (2016) · Hepatology · doi:10.1002/hep.28985 · Cited by 291 · see citing works
Self-citation
Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial
Yaskolka Meir, A., Rinott, E., Tsaban, G., Zelicha, H., Kaplan, A., Rosen, P., Shelef, I., Youngster, I., Shalev, A., Blüher, M., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-323106 · Cited by 287 · see citing works
Effects of Moderate and Vigorous Exercise on Nonalcoholic Fatty Liver Disease: A Randomized Clinical Trial
Zhang, H.-J., He, J., Pan, L.-L., Ma, Z.-M., Han, C.-K., Chen, C.-S., Chen, Z., Han, H.-W., Chen, S., Sun, Q., et al. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.3202 · Cited by 276 · see citing works
High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease
Kantartzis, K., Thamer, C., Peter, A., Machann, J., Schick, F., Schraml, C., Konigsrainer, A., Konigsrainer, I., Krober, S., Niess, A., et al. (2009) · Gut · doi:10.1136/gut.2008.151977 · Cited by 273 · see citing works
Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: A prospective randomized clinical trial using magnetic resonance imaging and spectroscopy
Dutour, A., Abdesselam, I., Ancel, P., Kober, F., Mrad, G., Darmon, P., Ronsin, O., Pradel, V., Lesavre, N., Martin, J. C., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12680 · Cited by 262 · see citing works
Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
Yan, J., Yao, B., Kuang, H., Yang, X., Huang, Q., Hong, T., Li, Y., Dou, J., Yang, W., Qin, G., et al. (2019) · Hepatology · doi:10.1002/hep.30320 · Cited by 260 · see citing works
The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: a randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients
Latva-Rasku, A., Honka, M.-J., Kullberg, J., Mononen, N., Lehtimäki, T., Saltevo, J., Kirjavainen, A. K., Saunavaara, V., Iozzo, P., Johansson, L., et al. (2019) · Diabetes Care · doi:10.2337/dc18-1569 · Cited by 253 · see citing works
Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999–2016
Zou, B., Yeo, Y. H., Nguyen, V. H., Cheung, R. C., Ingelsson, E., & Nguyen, M. H. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13069 · Cited by 250 · see citing works
Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)
Kuchay, M. S., Krishan, S., Mishra, S. K., Choudhary, N. S., Singh, M. K., Wasir, J. S., Kaur, P., Gill, H. K., Bano, T., Farooqui, K. J., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05265-7 · Cited by 249 · see citing works
Nonalcoholic Fatty Liver Disease
Zhao, Y.-C., Zhao, G., Chen, Z., She, Z., Cai, J., & Li, H. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.13419 · Cited by 244 · see citing works
Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients
Sookoian, S., & Pirola, C. J. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14112 · Cited by 230 · see citing works
Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes. The Lira-NAFLD study
Petit, J., Cercueil, J., Loffroy, R., Denimal, D., Bouillet, B., Fourmont, C., Chevallier, O., Duvillard, L., & Vergès, B. L. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2775 · Cited by 228 · see citing works
Ad libitum mediterranean and low-fat diets both significantly reduce hepatic steatosis: a randomized controlled trial
Properzi, C., O'Sullivan, T. A., Sherriff, J. L., Ching, H. L., Jeffrey, G. P., Buckley, R. F., Tibballs, J., MacQuillan, G. C., Garas, G., & Adams, L. A. (2018) · Hepatology · doi:10.1002/hep.30076 · Cited by 227 · see citing works
Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet—a randomised controlled trial
Holmer, M., Lindqvist, C., Petersson, S., Moshtaghi-Svensson, J., Tillander, V., Brismar, T. B., Hagström, H., & Stål, P. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100256 · Cited by 224 · see citing works
Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging
Flint, A., Andersen, G., Hockings, P., Johansson, L., Morsing, A., Sundby Palle, M., Vogl, T., Loomba, R., & Plum‐Mörschel, L. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16608 · Cited by 224 · see citing works
Exercise training reduces fatty acid availability and improves the insulin sensitivity of glucose metabolism
Shojaee‐Moradie, F., Baynes, K., Pentecost, C., Bell, J. D., Thomas, E. L., Jackson, N. C., Stolinski, M., Whyte, M., Lovell, D., Bowes, S. B., et al. (2006) · Diabetologia · doi:10.1007/s00125-006-0498-7 · Cited by 209 · see citing works
Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled Trial
Houghton, D., Thoma, C., Hallsworth, K., Cassidy, S., Hardy, T., Burt, A. D., Tiniakos, D., Hollingsworth, K. G., Taylor, R., Day, C. P., et al. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.07.031 · Cited by 209 · see citing works
Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?
Younes, R., Govaere, O., Petta, S., Miele, L., Tiniakos, D., Burt, A., David, E., Vecchio, F. M., Maggioni, M., Cabibi, D., et al. (2022) · Gut · doi:10.1136/gutjnl-2020-322564 · Cited by 205 · see citing works
Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes
Cusi, K., Bril, F., Barb, D., Polidori, D., Sha, S., Ghosh, A., Farrell, K., Sunny, N. E., Kalavalapalli, S., Pettus, J., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13584 · Cited by 204 · see citing works
Self-citation
Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes
Bril, F., Kalavalapalli, S., Clark, V. C., Lomonaco, R., Soldevila-Pico, C., Liu, I.-C., Orsak, B., Tio, F., & Cusi, K. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.12.001 · Cited by 199 · see citing works
Self-citation
Diet and Exercise Interventions Reduce Intrahepatic Fat Content and Improve Insulin Sensitivity in Obese Older Adults
Shah, K., Stufflebam, A., Hilton, T. N., Sinacore, D. R., Klein, S., & Villareal, D. T. (2009) · Obesity · doi:10.1038/oby.2009.126 · Cited by 194 · see citing works
Ethnic Variation in Adiponectin and Leptin Levels and Their Association With Adiposity and Insulin Resistance
Mente, A., Razak, F. A., Blankenberg, S., Vuksan, V., Davis, A. D., Miller, R., Teo, K. K., Gerstein, H. C., Sharma, A. M., Yusuf, S., et al. (2010) · Diabetes Care · doi:10.2337/dc09-1392 · Cited by 194 · see citing works
Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus
Lai, L.-L., Vethakkan, S. R., Nik Mustapha, N. R., Mahadeva, S., & Chan, W.-K. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-5477-1 · Cited by 191 · see citing works
Tuning fatty acid oxidation in skeletal muscle with dietary fat and exercise
Fritzen, A. M., Lundsgaard, A.-M., & Kiens, B. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0405-1 · Cited by 180 · see citing works
Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.
Younossi, Z. M., Tampi, R. P., Racila, A., Qiu, Y., Burns, L. C., Younossi, I. M., & Nader, F. (2019) · Diabetes Care · doi:10.2337/dc19-1113 · Cited by 179 · see citing works
Effect of liraglutide on ectopic fat in polycystic ovary syndrome: <scp>A</scp> randomized clinical trial
Frøssing, S., Nylander, M., Chabanova, E., Frystyk, J., Holst, J. J., Kistorp, C., Skouby, S. O., & Faber, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13053 · Cited by 178 · see citing works
Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD
Bril, F., Sninsky, J. J., Baca, A. M., Superko, H. R., Portillo-Sánchez, P., Biernacki, D., Maximos, M., Lomonaco, R., Orsak, B., Suman, A., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3111 · Cited by 168 · see citing works
Self-citation
Fatty Liver and Chronic Kidney Disease: Novel Mechanistic Insights and Therapeutic Opportunities
Musso, G., Cassader, M., Cohney, S. J., Michieli, F. D., Pinach, S., Saba, F., & Gambino, R. (2016) · Diabetes Care · doi:10.2337/dc15-1182 · Cited by 162 · see citing works
Nonalcoholic Fatty Liver Disease
Bril, F., & Cusi, K. J. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.06.005 · Cited by 152 · see citing works
Self-citation
Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension
Sung, K., Wild, S. H., & Byrne, C. D. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.01.009 · Cited by 151 · see citing works
Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis
de Vries, M., Westerink, J., Kaasjager, K. A. H., & de Valk, H. W. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa575 · Cited by 150 · see citing works
Adolescent Obesity and Insulin Resistance: Roles of Ectopic Fat Accumulation and Adipose Inflammation
Caprio, S., Perry, R. J., & Kursawe, R. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.12.051 · Cited by 143 · see citing works
Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Pouwels, P. J. W., Pieters-van den Bos, I. C., Hoekstra, T., Diamant, M., van Raalte, D. H., & Cahen, D. L. (2016) · Diabetologia · doi:10.1007/s00125-016-4100-7 · Cited by 142 · see citing works
Hyperinsulinemia and insulin resistance in the obese may develop as part of a homeostatic response to elevated free fatty acids: A mechanistic case-control and a population-based cohort study
Fryk, E., Olausson, J., Mossberg, K., Strindberg, L., Schmelz, M., Brogren, H., Gan, L., Piazza, S., Provenzani, A., Becattini, B., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103264 · Cited by 139 · see citing works
Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non‐alcoholic fatty liver disease
Khoo, J., Hsiang, J. C., Taneja, R., Koo, S., Soon, G., Kam, C. J., Law, N., & Ang, T. (2019) · Liver International · doi:10.1111/liv.14065 · Cited by 136 · see citing works
Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial
Tang, A., RABASA-LHORET, R. P. R., Castel, H., Wartelle‐Bladou, C., Gilbert, G., Massicotte-Tisluck, K., Chartrand, G., Olivié, D., Julien, A., de Guise, J. A., et al. (2015) · Diabetes Care · doi:10.2337/dc14-2548 · Cited by 133 · see citing works
Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: a single-centre randomized controlled study
Matikainen, N., Söderlund, S., Björnson, E., Pietiläinen, K., Hakkarainen, A., Lundbom, N., Taskinen, M., & Borén, J. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13487 · Cited by 129 · see citing works
Effect of aerobic exercise and diet on liver fat in pre-diabetic patients with non-alcoholic-fatty-liver-disease: A randomized controlled trial
Cheng, S., Ge, J., Zhao, C., Le, S., Yang, Y., Ke, D., Wu, N., Tan, X., Zhang, X., Du, X., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-16159-x · Cited by 127 · see citing works
Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: A pre-specified secondary study on ectopic fat accumulation
Bizino, M. B., Jazet, I. M., de Heer, P., van Eyk, H. J., Dekkers, I. A., Rensen, P. C. N., Paiman, E. H. M., Lamb, H. J., & Smit, J. W. (2020) · Diabetologia · doi:10.1007/s00125-019-05021-6 · Cited by 123 · see citing works
Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes
Liu, L., Yan, H., Xia, M., Zhao, L., Lv, M., Zhao, N., Rao, S., Yao, X., Wu, W., Pan, B., et al. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3292 · Cited by 119 · see citing works
Effect of Weight Loss on Liver Free Fatty Acid Uptake and Hepatic Insulin Resistance
Viljanen, A. P. M., Iozzo, P., Borra, R., Kankaanpää, M., Karmi, A., Läutamaki, R., Järvisalo, M. J., Parkkola, R. K., Rönnemaa, T., Guiducci, L., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1689 · Cited by 116 · see citing works
Exercise training reverses endothelial dysfunction in nonalcoholic fatty liver disease
Pugh, C. J. A., Sprung, V. S., Kemp, G. J., Richardson, P., Shojaee-Moradie, F., Umpleby, A. M., Green, D. J., Cable, N. T., Jones, H., & Cuthbertson, D. J. (2014) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00306.2014 · Cited by 116 · see citing works
Exercise Training Reduces Liver Fat and Increases Rates of VLDL Clearance But Not VLDL Production in NAFLD
Shojaee-Moradie, F., Cuthbertson, D. J., Barrett, M., Jackson, N. C., Herring, R., Thomas, E. L., Bell, J., Kemp, G. J., Wright, J., & Umpleby, A. M. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2353 · Cited by 116 · see citing works
Ethnicity Modifies the Relationships of Insulin Resistance, Inflammation, and Adiponectin With Obesity in a Multiethnic Asian Population
Khoo, C. M., Sairazi, S., Taslim, S., Gardner, D. S.-L., Wu, Y., Lee, J. Y., van Dam, R. M., & Tai, E. S. (2011) · Diabetes Care · doi:10.2337/dc10-2097 · Cited by 113 · see citing works
Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease
Kramer, J. R., Natarajan, Y., Dai, J., Yu, X., Li, L., El‐Serag, H. B., & Kanwal, F. (2021) · Hepatology · doi:10.1002/hep.32244 · Cited by 113 · see citing works
Effects of high-intensity interval and moderate-intensity continuous aerobic exercise on diabetic obese patients with nonalcoholic fatty liver disease
Abdelbasset, W. K., Tantawy, S. A., Kamel, D. M., Alqahtani, B. A., Elnegamy, T. E., Soliman, G. S., & Ibrahim, A. A. (2020) · Medicine · doi:10.1097/md.0000000000019471 · Cited by 110 · see citing works
Severe insulin resistance syndromes
Angelidi, A. M., Filippaios, A., & Mantzoros, C. S. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142245 · Cited by 108 · see citing works
Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non‐alcoholic fatty liver disease
Inoue, M., Hayashi, A., Taguchi, T., Arai, R., Sasaki, S., Takano, K., Inoue, Y., & Shichiri, M. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12980 · Cited by 105 · see citing works
Effects of a sodium‐glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: Preliminary prospective study based on serial liver biopsies
Akuta, N., Watanabe, C., Kawamura, Y., Arase, Y., Saitoh, S., Fujiyama, S., Sezaki, H., Hosaka, T., Kobayashi, M., Kobayashi, M., et al. (2017) · Hepatology Communications · doi:10.1002/hep4.1019 · Cited by 104 · see citing works
Improved hepatic lipid composition following short-term exercise in nonalcoholic fatty liver disease
Haus, J. M., Solomon, T. P. J., Kelly, K. R., Fealy, C. E., Kullman, E. L., Scelsi, A. R., Lu, L., Pagadala, M. R., McCullough, A. J., Flask, C. A., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1229 · Cited by 100 · see citing works
Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial
Yoneda, M., Honda, Y., Ogawa, Y., Kessoku, T., Kobayashi, T., Imajo, K., Ozaki, A., Nogami, A., Taguri, M., Yamanaka, T., et al. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001990 · Cited by 100 · see citing works
Lipid-Induced Insulin Resistance in Skeletal Muscle: The Chase for the Culprit Goes from Total Intramuscular Fat to Lipid Intermediates, and Finally to Species of Lipid Intermediates
Kitessa, S., & Abeywardena, M. (2016) · Nutrients · doi:10.3390/nu8080466 · Cited by 98 · see citing works
Practice patterns in NAFLD and NASH: real life differs from published guidelines
Rinella, M. E., Lominadze, Z., Loomba, R. S., Charlton, M., Neuschwander‐Tetri, B. A., Caldwell, S. H., Kowdley, K. V., & Harrison, S. A. (2015) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x15611581 · Cited by 95 · see citing works
Alterations in Fatty Acid Kinetics in Obese Adolescents With Increased Intrahepatic Triglyceride Content
Fabbrini, E., DeHaseth, D., Deivanayagam, S., Mohammed, B. S., Vitola, B. E., & Klein, S. (2008) · Obesity · doi:10.1038/oby.2008.494 · Cited by 94 · see citing works
Hepatic Insulin Resistance Is Not Pathway Selective in Humans With Nonalcoholic Fatty Liver Disease
ter Horst, K. W., Vatner, D. F., Zhang, D., Cline, G. W., Ackermans, M. T., Nederveen, A. J., Verheij, J., Demirkiran, A., van Wagensveld, B. A., Dallinga-Thie, G. M., et al. (2021) · Diabetes Care · doi:10.2337/dc20-1644 · Cited by 88 · see citing works
The Metabolic and Hepatic Impact of Two Personalized Dietary Strategies in Subjects with Obesity and Nonalcoholic Fatty Liver Disease: The Fatty Liver in Obesity (FLiO) Randomized Controlled Trial
Marín-Alejandre, B. A., Abete, I., Cantero, I., Monreal, J. I., Elorz, M., Herrero, J. I., Benito, A., Quiroga, J. A., Martinez‐Echeverria, A., Úriz-Otano, J. I., et al. (2019) · Nutrients · doi:10.3390/nu11102543 · Cited by 84 · see citing works
Association of genetic variations with NAFLD in lean individuals
Lin, H., Wong, G. L., Whatling, C. A., Chan, A. W. H., Leung, H. H. W., Tse, C., Shu, S. S., Chim, A. M.-L., Lai, J. C., Yip, T. C., et al. (2021) · Liver International · doi:10.1111/liv.15078 · Cited by 80 · see citing works
Impact of Lipotoxicity on Tissue “Cross Talk” and Metabolic Regulation
Montgomery, M. K., Nardo, W. D., & Watt, M. J. (2019) · Physiology · doi:10.1152/physiol.00037.2018 · Cited by 78 · see citing works
Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study
Cusi, K. J., Alkhouri, N., Harrison, S. A., Fouqueray, P., Moller, D. E., Hallakou‐Bozec, S., Bolze, S., Grouin, J., Megnien, S. J., Dubourg, J., et al. (2021) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(21)00300-9 · Cited by 78 · see citing works
Self-citation
Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin
Vanderheiden, A., Harrison, L., Warshauer, J. T., ADAMS-HUET, B. A., Li, X., Yuan, Q., Hulsey, K., Dimitrov, I. E., Yokoo, T., Jaster, A. W., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3906 · Cited by 76 · see citing works
Correspondence Between the Adult Treatment Panel III Criteria for Metabolic Syndrome and Insulin Resistance
Sierra‐Johnson, J., Johnson, B. D., Allison, T. G., Bailey, K. R., Schwartz, G. L., & Turner, S. T. (2006) · Diabetes Care · doi:10.2337/diacare.29.03.06.dc05-0970 · Cited by 70 · see citing works
Circulating Triacylglycerol Signatures in Nonalcoholic Fatty Liver Disease Associated With the I148M Variant in PNPLA3 and With Obesity
Hyysalo, J., Gopalacharyulu, P. V., Bian, H., Hyötyläinen, T., Leivonen, M., Jaser, N., Juuti, A., Honka, M., Nuutila, P., Olkkonen, V. M., et al. (2013) · Diabetes · doi:10.2337/db13-0774 · Cited by 61 · see citing works
Impaired Hepatic Mitochondrial Capacity in Nonalcoholic Steatohepatitis Associated With Type 2 Diabetes
Gancheva, S., Kahl, S., Pesta, D., Mastrototaro, L., Dewidar, B., Strassburger, K., Sabah, E., Esposito, I., Weiß, J., Sarabhai, T., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1758 · Cited by 60 · see citing works
Physiological hyperinsulinemia impairs insulin-stimulated glycogen synthase activity and glycogen synthesis
Iozzo, P., Pratipanawatr, T., Pijl, H., Vogt, C., Kumar, V., Pipek, R., Matsuda, M., Mandarino, L. J., Cusi, K. J., & DeFronzo, R. A. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.280.5.e712 · Cited by 57 · see citing works
Self-citation
Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes
Ohta, A., Kato, H., Ishii, S., Sasaki, Y., Nakamura, Y., Nakagawa, T., Nagai, Y., & Tanaka, Y. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1363888 · Cited by 56 · see citing works
Insulin resistance in lean and overweight non-diabetic Caucasian adults: study of its relationship with liver triglyceride content, waist circumference and BMI
Gonzalez-Cantero, J., Martin-Rodriguez, J. L., Gonzalez-Cantero, A., Arrebola, J. P., & Gonzalez-Calvin, J. L. (2018) · PLOS ONE · doi:10.1371/journal.pone.0192663 · Cited by 51 · see citing works
Effect of orlistat on liver fat content in patients with nonalcoholic fatty liver disease with obesity: assessment using magnetic resonance imaging-derived proton density fat fraction
Ye, J., Wu, Y., Li, F., Wu, T., Shao, C., Lin, Y., Wang, W., Feng, S., & Zhong, B. (2019) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284819879047 · Cited by 51 · see citing works
Dapagliflozin plus saxagliptin add‐on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes
Johansson, L., Hockings, P. D., JOHNSSON, E. K., Dronamraju, N., Maaske, J., García‐Sánchez, R., & Wilding, J. P. H. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14004 · Cited by 43 · see citing works
Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients
Bril, F., Portillo-Sánchez, P., Liu, I., Kalavalapalli, S., Dayton, K., & Cusi, K. J. (2017) · Diabetes Care · doi:10.2337/dc17-1349 · Cited by 42 · see citing works
Self-citation
Effect of resistance training on liver fat and visceral adiposity in adults with obesity: A randomized controlled trial
Keating, S. E., Hackett, D. A., Parker, H. M., Way, K. L., O'Connor, H. T., Sainsbury, A., Baker, M. K., Chuter, V., Caterson, I. D., George, J., et al. (2016) · Hepatology Research · doi:10.1111/hepr.12781 · Cited by 41 · see citing works
Monitoring Fatty Liver Disease with MRI Following Bariatric Surgery: A Prospective, Dual-Center Study
Pooler, B. D., Wiens, C. N., McMillan, A., Artz, N. S., Schlein, A., Covarrubias, Y., Hooker, J., Schwimmer, J. B., Funk, L. M., Campos, G. M., et al. (2019) · Radiology · doi:10.1148/radiol.2018181134 · Cited by 37 · see citing works
Could inherited predisposition drive non-obese fatty liver disease? Results from German tertiary referral centers
Krawczyk, M. J., Bantel, H., Rau, M., Schattenberg, J. M., Grünhage, F., Pathil, A., Demir, M., Kluwe, J., Boettler, T., Weber, S. N., et al. (2018) · Journal of Human Genetics · doi:10.1038/s10038-018-0420-4 · Cited by 36 · see citing works
Association between metabolic syndrome and liver histology among NAFLD patients without diabetes
Kanwar, P., Nelson, J. E., Yates, K. P., et al. (2016) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2016-000114 · Cited by 34 · see citing works
Race affects the association of obesity measures with insulin sensitivity
Tay, J., Goss, A. M., Garvey, W. T., Lockhart, M. E., Bush, N. C., Quon, M. J., Fisher, G., & Gower, B. A. (2019) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqz309 · Cited by 33 · see citing works
The challenge of managing dyslipidemia in patients with nonalcoholic fatty liver disease
Bril, F., Lomonaco, R., & Cusi, K. J. (2012) · Clinical Lipidology · doi:10.2217/clp.12.47 · Cited by 32 · see citing works
Self-citation
Energy Expenditure Improved Risk Factors Associated with Renal Function Loss in NAFLD and MetS Patients
Abbate, M., Mascaró, C. M., Montemayor, S., Barbería-Latasa, M., Casares, M., Gómez, C., Angullo-Martínez, E., Tejada, S., Abete, I., Zulet, M. Á., et al. (2021) · Nutrients · doi:10.3390/nu13020629 · Cited by 28 · see citing works
Liver fat accumulation as a barometer of insulin responsiveness again points to adipose tissue as the culprit
Rotman, Y., & Neuschwander‐Tetri, B. A. (2017) · Hepatology · doi:10.1002/hep.29094 · Cited by 27 · see citing works
Potential effects of reduced red meat compared with increased fiber intake on glucose metabolism and liver fat content: a randomized and controlled dietary intervention study
Willmann, C., Heni, M., Linder, K., Wagner, R. J., Stefan, N., Machann, J., Schulze, M. B., Joost, H., Häring, H., & Fritsche, A. (2018) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqy307 · Cited by 27 · see citing works
PNPLA3 gene polymorphism and overall and cardiovascular mortality in the United States
Wijarnpreecha, K., Scribani, M., Raymond, P., Harnois, D. M., Keaveny, A. P., Ahmed, A., & Kim, D. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15045 · Cited by 27 · see citing works
African Americans have a distinct clinical and histologic profile with lower prevalence of NASH and advanced fibrosis relative to Caucasians
Satapathy, S. K., Marella, H. K., Heda, R. P., Ganguli, S., Reddy, Y. K., Podila, P. S. B., Clark, I., & Maliakkal, B. J. (2020) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001735 · Cited by 14 · see citing works
CrossTalk proposal: Intramuscular lipid accumulation causes insulin resistance
Goodpaster, B. H. (2020) · The Journal of Physiology · doi:10.1113/jp278219 · Cited by 12 · see citing works
Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver
Leiva, E. G., & Bril, F. (2020) · Current Hypertension Reviews · doi:10.2174/1573402116999201209203534 · Cited by 11 · see citing works
Self-citation
Treatment of hyperglycemia not associated with NAFLD improvement in children with type 2 diabetes mellitus
Beauchamp, G., Barr, M. M., Vergara, A., Ashraf, A. P., & Bril, F. (2021) · International Journal of Pediatrics and Adolescent Medicine · doi:10.1016/j.ijpam.2021.02.007 · Cited by 11 · see citing works
Self-citation
Nonalcoholic steatohepatitis medical patient journey from the perspective of hepatologists, gastroenterologists and patients: a cross-sectional survey
Rinella, M. E., Cryer, D. R. H., Articolo, A., Fisher, T., Schneider, J. L., & Nadolsky, K. Z. (2022) · BMC Gastroenterology · doi:10.1186/s12876-022-02410-x · Cited by 11 · see citing works
Insulin sensitivity and kinetics in African American and White people with obesity: Insights from different study protocols
Koh, H. E., Patterson, B. W., Reeds, D. N., & Mittendorfer, B. (2022) · Obesity · doi:10.1002/oby.23363 · Cited by 8 · see citing works
Effect of Endurance Exercise on Non-Alcoholic Fatty Liver Disease
Sullivan, S. A., Kirk, E. P., Patterson, B. W., & Klein, S. (2011) · Gastroenterology · doi:10.1016/s0016-5085(11)62910-7 · Cited by 7 · see citing works

Flagged first, then by citations

Sorted by citations

EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210 · see citing works
Exercise in the Management of Metabolic-Associated Fatty Liver Disease (MAFLD) in Adults: A Position Statement from Exercise and Sport Science Australia
Keating, S. E., Sabag, A., Hallsworth, K., Hickman, I. J., Macdonald, G. A., Stine, J. G., George, J., & Johnson, N. A. (2023) · Sports Medicine · doi:10.1007/s40279-023-01918-w · Cited by 119 · see citing works
RETRACTED: Loss of mitochondrial adaptation associates with deterioration of mitochondrial turnover and structure in metabolic dysfunction-associated steatotic liver disease
Sarabhai, T., Kahl, S., Gancheva, S., Mastrototaro, L., Dewidar, B., Pesta, D., Ratter-Rieck, J. M., Bobrov, P., Jeruschke, K., Esposito, I., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2023.155762 · Cited by 9 · see citing works
Retracted

Authors: Bril, F., Sanyal, A., & Cusi, K.
Affiliations: University of Alabama at Birmingham (US)
Virginia Commonwealth University (US)
University of Florida Health (US)
Corresponding author: Bril, Fernando
ORCID: Bril, Fernando
Sanyal, Arun
Cusi, Kenneth
Venue: Clinics in Liver Disease
Publisher: Elsevier BV
Published: 2023-05
Volume: 27
Issue: 2
Pages: 187-210
ISSN: 1089-3261 (ISSN-L)
DOI: 10.1016/j.cld.2023.01.002
OpenAlex: W4322208288
Cited by: 52
References: 149
Citations by year: 2026: 11 · 2025: 13 · 2024: 23 · 2023: 5
FWCI: 2.02
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (am, 339 d)
doi.org/10.15223/policy-017 (stm-asf)
doi.org/10.15223/policy-037 (stm-asf)
doi.org/10.15223/policy-012 (stm-asf)
doi.org/10.15223/policy-029 (stm-asf)
doi.org/10.15223/policy-004 (stm-asf)
Locations: Clinics in Liver Disease (acceptedVersion)
PubMed (publishedVersion)
Funders: Gilead Sciences
National Institutes of Health
Eli Lilly and Company
Topics: Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
Keywords: metabolic syndrome, nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, insulin resistance, cardiometabolic risk factors, metabolic dysfunction, disease classification
MeSH terms: Humans, Insulin Resistance, Metabolic Syndrome, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Metabolic syndrome and its association with nonalcoholic steatohepatitis

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks